ATE258066T1 - Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix) - Google Patents
Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix)Info
- Publication number
- ATE258066T1 ATE258066T1 AT97905539T AT97905539T ATE258066T1 AT E258066 T1 ATE258066 T1 AT E258066T1 AT 97905539 T AT97905539 T AT 97905539T AT 97905539 T AT97905539 T AT 97905539T AT E258066 T1 ATE258066 T1 AT E258066T1
- Authority
- AT
- Austria
- Prior art keywords
- iscom
- matrix
- immunstimulative
- complex
- bonded
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600648A SE9600648D0 (sv) | 1996-02-21 | 1996-02-21 | Receptorbimdande enhet |
| PCT/SE1997/000287 WO1997030726A1 (en) | 1996-02-21 | 1997-02-20 | Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE258066T1 true ATE258066T1 (de) | 2004-02-15 |
Family
ID=20401482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97905539T ATE258066T1 (de) | 1996-02-21 | 1997-02-20 | Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6027732A (pt) |
| EP (1) | EP0944397B1 (pt) |
| AT (1) | ATE258066T1 (pt) |
| AU (1) | AU718443B2 (pt) |
| BR (1) | BR9707638A (pt) |
| CA (1) | CA2247103C (pt) |
| DE (1) | DE69727314T2 (pt) |
| DK (1) | DK0944397T3 (pt) |
| ES (1) | ES2214608T3 (pt) |
| NZ (1) | NZ331418A (pt) |
| SE (1) | SE9600648D0 (pt) |
| WO (1) | WO1997030726A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US7776343B1 (en) * | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
| EP1239876B1 (en) * | 1999-11-19 | 2008-07-30 | Csl Limited | Hcv vaccine compositions |
| SE0003538D0 (sv) * | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
| IL162857A0 (en) * | 2002-01-15 | 2005-11-20 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Oral vaccination |
| WO2004087203A2 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
| KR100958505B1 (ko) * | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
| CN101516396B (zh) | 2006-09-26 | 2013-10-09 | 传染性疾病研究院 | 包含合成佐剂的疫苗组合物 |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| ES2325243B1 (es) * | 2008-02-27 | 2011-05-04 | Universidad De Granada | Antigeno recombinante. |
| US8722064B2 (en) | 2009-06-05 | 2014-05-13 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| EP3632463A1 (en) | 2011-04-08 | 2020-04-08 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
| NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
| EP3711768A1 (en) | 2013-04-18 | 2020-09-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| EP3915579A1 (en) | 2013-12-31 | 2021-12-01 | Infectious Disease Research Institute | Single vial vaccine formulations |
| MX2021014363A (es) | 2019-05-25 | 2022-02-21 | Infectious Disease Res Inst | Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante. |
| EP4058581A1 (en) | 2019-11-15 | 2022-09-21 | Infectious Disease Research Institute | Rig-i agonist and adjuvant formulation for tumor treatment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2403081A1 (fr) * | 1977-09-19 | 1979-04-13 | Merieux Inst | Nouveau materiau particulaire, sa preparation et son application, notamment comme medicament |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
-
1996
- 1996-02-21 SE SE9600648A patent/SE9600648D0/xx unknown
-
1997
- 1997-02-20 ES ES97905539T patent/ES2214608T3/es not_active Expired - Lifetime
- 1997-02-20 DE DE1997627314 patent/DE69727314T2/de not_active Expired - Lifetime
- 1997-02-20 DK DK97905539T patent/DK0944397T3/da active
- 1997-02-20 AT AT97905539T patent/ATE258066T1/de not_active IP Right Cessation
- 1997-02-20 WO PCT/SE1997/000287 patent/WO1997030726A1/en active IP Right Grant
- 1997-02-20 BR BR9707638-4A patent/BR9707638A/pt not_active IP Right Cessation
- 1997-02-20 NZ NZ331418A patent/NZ331418A/xx not_active IP Right Cessation
- 1997-02-20 EP EP97905539A patent/EP0944397B1/en not_active Expired - Lifetime
- 1997-02-20 US US09/125,588 patent/US6027732A/en not_active Expired - Lifetime
- 1997-02-20 AU AU22383/97A patent/AU718443B2/en not_active Expired
- 1997-02-20 CA CA002247103A patent/CA2247103C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6027732A (en) | 2000-02-22 |
| ES2214608T3 (es) | 2004-09-16 |
| SE9600648D0 (sv) | 1996-02-21 |
| CA2247103C (en) | 2009-01-20 |
| DK0944397T3 (da) | 2004-06-01 |
| CA2247103A1 (en) | 1997-08-28 |
| AU2238397A (en) | 1997-09-10 |
| EP0944397B1 (en) | 2004-01-21 |
| NZ331418A (en) | 2000-03-27 |
| DE69727314D1 (de) | 2004-02-26 |
| DE69727314T2 (de) | 2004-11-18 |
| BR9707638A (pt) | 2000-01-04 |
| AU718443B2 (en) | 2000-04-13 |
| EP0944397A1 (en) | 1999-09-29 |
| WO1997030726A1 (en) | 1997-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE258066T1 (de) | Ein hydrophobes rezeptormolekül für antigene stoffen enthaltender immunstimulierender komplex (iscom) oder matrix gebundener immunstimulierender komplex (iscom-matrix) | |
| BR0315123A (pt) | Composições farmacêuticas direcionadas a receptores erb-b1 | |
| DE69919692D1 (de) | Verabreichungssystem für Impstoffe basierend auf Gonokokkenblebosomen | |
| DE69800716T2 (de) | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen | |
| DK1066060T3 (da) | Mesenkymale stamceller som immunsuppresive midler | |
| CY1111863T1 (el) | Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων | |
| CL2012001063A1 (es) | Anticuerpo humano que se une a interleuquina 18 humana (il-18h), metodo de preparacion, acidos nucleicos que lo dosifican, composicion que los contiene, uso en la preparacion de un medicamento para tratar patologias mediadas por il-18h. (divisional sol. 316-01). | |
| MX9804358A (es) | Apoptosis inducida por el anticuerpo monoclonal anti-her2. | |
| ATE197592T1 (de) | Monoklonaler antikörper gegen cd44v6 | |
| ES2196150T3 (es) | Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion. | |
| BR0116686A (pt) | Anticorpos anti-cd28 silenciados e uso dos mesmos | |
| ATE160839T1 (de) | Ausfachsystem für wände und verkleidungen im bauwesen | |
| TR199902585T2 (xx) | Elyafl� par�ac�klar�n franksiyonlanmas� ve da��t�lmas�na mahsus tertibat. | |
| Hübscher et al. | Bundesdeutsche Arbeitsgemeinschaft für Veränderliche Sterne eV (BAV): Beobachtungsergebnisse. | |
| ES2163001T3 (es) | Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. | |
| DE69633635D1 (de) | Spezifischer immunstimulierender factor mit hoher fluoreszens und verfahren für dessen verwendung | |
| UA29496C2 (uk) | Ротор для перемішуючих пристроїв | |
| Zhao et al. | VizieR Online Data Catalog: Tables of membership for 43 open clusters (Zhao+, 1995) | |
| ATE209041T1 (de) | Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung | |
| ATE328088T1 (de) | Transketolase-verwandtes protein | |
| Davoust et al. | VizieR Online Data Catalog: Bibliography of Surface Photometry of galaxies (Davoust+ 1982) | |
| Castilho et al. | VizieR Online Data Catalog: HD 146850 atomic lines (Castilho+, 1995) | |
| ES2116946B1 (es) | Composicion para la obtencion de un aguardiente. | |
| Prosser et al. | VizieR Online Data Catalog: Alpha Per cluster low-mass members. I.(Prosser+, 1998) | |
| Nousek et al. | X-ray Halos in the Eclipsing Binary 1H0253+ 193 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0944397 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |